Picture loading failed.

Pre-Made Vixarelimab biosimilar, Whole mAb, Anti-OSMR Antibody: Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Vixarelimab is an investigational fully-human monoclonal antibody that targets OSMRβ, which mediates signaling of interleukin-31 (IL-31) and oncostatin M (OSM), two key cytokines implicated in pruritus, inflammation and fibrosis.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-623-1mg 1mg 3090
GMP-Bios-ab-623-10mg 10mg 21890
GMP-Bios-ab-623-100mg 100mg 148000
GMP-Bios-ab-623-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vixarelimab biosimilar, Whole mAb, Anti-OSMR Antibody: Anti-IL-31R-beta/IL-31RB/OSMRB/OSMRbeta/PLCA1 therapeutic antibody
INN Name Vixarelimab
TargetOSMR
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4-G1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesKiniksa Pharmaceuticals
Conditions Approvedna
Conditions ActivePrurigo nodularis;Pruritus;Atopic dermatitis
Conditions Discontinuedna
Development Techna